CLINICAL TRIALS PROFILE FOR EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
✉ Email this page to a colleague
All Clinical Trials for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01497899 ↗ | Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | Completed | Gilead Sciences | Phase 2 | 2011-12-28 | The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults. |
NCT01565850 ↗ | D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults | Completed | Gilead Sciences | Phase 2 | 2012-04-01 | This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24. |
NCT01780506 ↗ | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | Completed | Gilead Sciences | Phase 3 | 2012-12-26 | The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults. |
NCT01797445 ↗ | Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | Completed | Gilead Sciences | Phase 3 | 2013-03-12 | The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Condition Name
Condition MeSH
Clinical Trial Locations for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Trials by Country
Clinical Trial Progress for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor Name
Sponsor Name for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | |
Sponsor | Trials |
Gilead Sciences | 25 |
National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
University of California, San Diego | 2 |
[disabled in preview] | 1 |
This preview shows a limited data set Subscribe for full access, or try a Trial |